# PragmaTIL (EU Cancer Mission trial of TIL therapy with an IL-2 analogue)

Source: https://onco.cc/trials/pragmatil/  
OnCo record `pragmatil` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A European trial testing whether a gentler substitute for high-dose interleukin-2, the drug given after tumour-infiltrating lymphocyte cell therapy, can cut serious side effects while keeping the treatment working, in melanoma, lung and cervical cancer.

## Summary

PragmaTIL is a Horizon Europe Cancer Mission project (CORDIS 101104684, topic HORIZON-MISS-2022-CANCER-01-03, "Pragmatic clinical trials to optimise treatments for patients with refractory cancers"), coordinated by the Vall d'Hebron Institute of Oncology in Barcelona, running from 1 April 2023 to 31 March 2028 with an EU contribution of about EUR 6.0 million. Tumour-infiltrating lymphocyte adoptive cell therapy normally requires high-dose interleukin-2 to expand and activate the infused cells, and its toxicity is a barrier to use. The project's objectives are to find whether an IL-2 analogue reduces the frequency of grade 3 or higher non-haematological study-related toxicity, to compare quality of life in hospital and over time, and to carry out a health technology assessment and a social return on investment analysis.

ClinicalTrials.gov lists it as NCT06630611, a phase 2 study sponsored by Vall d'Hebron Institute of Oncology in melanoma, non-small-cell lung cancer and cervical cancer, recruiting, with an actual start on 15 January 2025 and a planned enrolment of 40, comparing an IL-2 analogue with high-dose IL-2 after non-myeloablative lymphodepletion and TIL infusion.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Also known as: PragmaTIL
- Registry id: NCT06630611
- Phase: 2
- Setting: Melanoma, non-small-cell lung cancer and cervical cancer: tumour-infiltrating lymphocyte therapy with an IL-2 analogue versus high-dose IL-2
- Sponsor: Vall d'Hebron Institute of Oncology
- Enrolled: 40

## Notes

- The IL-2 analogue is named ANV600 in the CORDIS objective and ANV419 in the ClinicalTrials.gov title, both read on 4 November 2026; the record does not choose between them and links no drug record.
- No results have been reported.

## Sources

- ClinicalTrials.gov: NCT06630611: https://clinicaltrials.gov/study/NCT06630611
- CORDIS: PragmaTIL (101104684): https://cordis.europa.eu/project/id/101104684

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [TIL therapy](https://onco.cc/technologies/til-therapy/)
- institutions: [EU Mission on Cancer (Horizon Europe)](https://onco.cc/institutions/eu-mission-on-cancer/), [Vall d'Hebron University Hospital / VHIO](https://onco.cc/institutions/vall-dhebron/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)

---
JSON: https://onco.cc/api/v1/entities/pragmatil.json